Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

Ning Ma1 Peking University Sixth Hospital, Beijing, People’s Republic of China;2 Peking University Institute of Mental Health, Beijing, People’s Republic of China;3 NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information

Lei Zhang4 Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of ChinaView further author information

Wufang Zhang1 Peking University Sixth Hospital, Beijing, People’s Republic of China;2 Peking University Institute of Mental Health, Beijing, People’s Republic of China;3 NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of ChinaView further author information

Yingying He1 Peking University Sixth Hospital, Beijing, People’s Republic of China;2 Peking University Institute of Mental Health, Beijing, People’s Republic of China;3 NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of ChinaView further author information

Chong Ye4 Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China

https://orcid.org/0000-0001-7111-8514 View further author information

Xin Li4 Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of ChinaView further author information

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date